SEC Form 4 · accession 0001209191-16-095840

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP\Chief Commercial Officer

Period of report

Feb 2, 2016

Accepted (ET)

Feb 4, 2016 · 6:51 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Feb 2, 2016	A	17,299	$0.01	A	121,763	D
Common Stock^F2,F3	Feb 3, 2016	S	2,597	$89.92	D	119,166	D
Common Stock^F3,F4	Feb 3, 2016	S	2,100	$90.98	D	117,066	D
Common Stock^F3,F5	Feb 3, 2016	S	700	$91.89	D	116,366	D
Common Stock^F3,F6	Feb 3, 2016	S	645	$92.80	D	115,721	D
Common Stock	holding	—	—		—	140	I	401(k)

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$91.05	Feb 2, 2016	A	34,482	A	—	Feb 1, 2026	Common Stock	34,482	34,482	D

F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $89.92 (range $89.31 to $90.27).
F3Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $90.98 (range $90.38 to $91.32).
F5Open market sales reported on this line occurred at a weighted average price of $91.89 (range $91.38 to $92.35).
F6Open market sales reported on this line occurred at a weighted average price of $92.80 (range $92.40 to $93.03).
F7The option vests in 16 quarterly installments from 02/02/2016.